Skip to main content

Table 4 Cytokines and coagulation parameters in 73 COVID-19 patients stratified according to high (≥ median) versus low (< median) MCP-1

From: IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19

  Total (N = 73) MCP-1 P
Low (N = 27) High (N = 46)
n Median (IQR) n Median (IQR) n Median (IQR)
IL-1β, pg/mL 29 5.0 (5.0–5.0) 8 5.0 (5.0–5.0) 21 5.0 (5.0–5.9) 0.491
IL-2R, U/mL 29 1059.0 (460.0–1642.0) 8 1075.0 (382.0–1674.5) 21 1059.0 (518.5–1754.0) 0.391
IL-6, pg/mL 48 74.2 (17.0–157.5) 20 19.1 (8.7–93.1) 28 114.3 (38.2–353.1) 0.001
IL-8, pg/mL 29 51.7 (12.5–114.7) 8 20.3 (10.6–30.6) 21 77.0 (16.2–163.0) 0.064
IL-10, pg/mL 29 11.4 (5.0–20.1) 8 5.0 (5.0–16.4) 21 11.7 (5.4–31.6) 0.095
TNFα, pg/mL 27 12.7 (7.5–28.7) 8 8.6 (6.4–13.8) 19 13.3 (7.9–30.5) 0.27
Prothrombin time (PT), s 71 15.9 (14.9–18.2) 26 15.0 (14.2–16.1) 45 17.0 (15.6–19.0) 0.001
Prothrombin activity (PTA), % 71 69.0 (55.0–80.0) 26 77.5 (68.3–88.0) 45 62.0 (51.0–71.5) 0.001
International normalized ratio (INR) 71 1.26 (1.15–1.49) 26 1.17 (1.09–1.28) 45 1.37 (1.23–1.58) 0.001
Fibrinogen (FIB), g/L 71 4.2 (3.1–5.2) 26 4.1 (3.4–5.1) 45 4.4 (3.0–5.3) 0.878
Activated partial thromboplastin time (APTT), s 71 44.5 (39.3–52.6) 26 43.3 (37.9–50.6) 45 45.4 (40.0–56.1) 0.228
Thrombin time (TT), s 71 15.3 (14.5–16.5) 26 15.2 (14.5–16.1) 45 15.4 (14.6–17.6) 0.316
d-dimer, μg/mL FEU 71 3.85 (1.68–13.46) 26 2.03 (1.25–5.48) 45 6.30 (2.52–15.76) 0.005
Fibrin degradation products (FDP), μg/mL 30 17.2 (6.2–68.6) 9 5.7 (4.0–38.7) 21 32.6 (13.6–130.5) 0.019
Antithrombin (AT), % 34 80.5 (65.5–88.5) 11 84.0 (78.0–93.0) 23 75.0 (60.0–86.0) 0.12
  1. Bold indicates the statistically significant values (P < 0.05)